BSW Area Prescribing Committee

Clinical Policies Drugs and Devices

The following clinical policies have been developed across BSW for HCD drugs and Devices which are excluded from the tariff.

Policy for Funding Flash Glucose Monitoring for People with Diabetes
BSW Vedolizumab Dose Escalation Policy for IBD
BSW Infliximab Dose Escalation Policy for IBD
BSW Ustekinumab Dose Escalation Policy for Crohn's Disease
Policy for use of AvastinĀ® (bevacizumab) under the NICE threshold in wet AMD
Policy for the use of sodium hyaluronic acid injections in osteoarthritis
Bevacizumab for the treatment of rubeotic/neovascular glaucoma and uncontrolled Proliferative Diabetic Retinopathy prior to laser or vitrectomy (adults)
Policy for dose escalation of Ustekinumab in psoriasis or psoriatic arthritis
BSW Qutenza patch (capsaicin 8%) for peripheral neuropathic pain in non-diabetic patients commissioning statement: Low priority intervention
BSW Use of Qutenza Patches in Adults for Peripheral Neuropathic pain in non-diabetic patients: Prior Approval Form
BSW Sativex commissioning statement March 2021